Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Propella Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 2 art units, reflecting separate examination channels.
OTTON, ALICIA L is the listed busiest examiner, with 1 pending matter. Counsel should track each action independently while coordinating technical positions across the pharmaceutical portfolio when the records support doing so.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920358 | ABIRATERONE PRODRUGS | OTTON, ALICIA L | 1699 | §103Other | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18842725 | ABIRATERONE DECANOATE PRODRUGS AND USE IN THERAPY | AGGARWAL, SAHIL CHANDER | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Aug 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPropella Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Alicia L Otton has the most, with 1 of Propella Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
